このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Creative Medical Technology Holdings 将来の成長

Future 基準チェック /56

Creative Medical Technology Holdingsは、67.1%と67.7%でそれぞれ年率67.1%で利益と収益が成長すると予測される一方、EPSはgrowで65.3%年率。

主要情報

67.1%

収益成長率

65.3%

EPS成長率

Biotechs 収益成長	30.2%
収益成長率	67.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	24 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

NasdaqCM:CELZ - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	23	9	N/A	N/A	1
12/31/2025	1	-4	N/A	N/A	1
12/31/2024	N/A	-5	N/A	N/A	1
6/30/2024	0	-6	-6	-6	N/A
3/31/2024	0	-5	-5	-5	N/A
12/31/2023	0	-5	-8	-8	N/A
9/30/2023	0	-10	-10	-10	N/A
6/30/2023	0	-9	-9	-9	N/A
3/31/2023	0	-10	-10	-10	N/A
12/31/2022	0	-10	-8	-8	N/A
9/30/2022	0	-8	-5	-5	N/A
6/30/2022	0	-9	-5	-5	N/A
3/31/2022	0	-10	-3	-3	N/A
12/31/2021	0	19	-2	-2	N/A
9/30/2021	0	-16	-1	-1	N/A
6/30/2021	0	-13	-1	-1	N/A
3/31/2021	0	-12	-1	-1	N/A
12/31/2020	0	-36	-1	0	N/A
9/30/2020	0	-3	-1	-1	N/A
6/30/2020	0	-6	-1	-1	N/A
3/31/2020	0	-4	-1	-1	N/A
12/31/2019	0	-8	-1	-1	N/A
9/30/2019	0	-1	-1	-1	N/A
6/30/2019	0	-1	-1	-1	N/A
3/31/2019	0	-7	-1	-1	N/A
12/31/2018	0	-14	-1	-1	N/A
9/30/2018	0	-17	-1	-1	N/A
6/30/2018	0	-16	-1	-1	N/A
3/31/2018	0	-10	N/A	-1	N/A
12/31/2017	0	-3	N/A	-1	N/A
9/30/2017	N/A	-1	N/A	-1	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	N/A	-1	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CELZは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.5% ) よりも高い成長率であると考えられます。

収益対市場: CELZ今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: CELZ今後 3 年以内に収益を上げることが予想されます。

収益対市場: CELZの収益 ( 67.7% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: CELZの収益 ( 67.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CELZの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Creative Medical Technology Holdings 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem

New major risk - Financial position

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain

Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing Requirements

Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform

Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot Study

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Receives Non-Compliance Notice from Nasdaq

Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in funding

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

High number of new and inexperienced directors

Creative Medical Technology Holdings Deleted from Other OTC

Less than half of directors are independent

Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in funding

Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in funding

Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke Treatment

Creative Medical Technology Holdings, Inc. Announces Fda Acknowledgment of Ind Application for Immcelz® to Treat Stroke

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using Stemspine® Personalized Adult Stem Cell Therapy

Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection Using ImmCelz®

Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented Ovastem® Female Infertility/Ovarian Failure Treatment

Creative Medical Technology Holdings, Inc. Announces the Recruitment of Dr. Caigan Du to the Scientific Advisory Board

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of Immcelz® Therapeutic Activity

Creative Medical Technology Holdings Inc. Recruits Dr. Boris Reznik to the Scientific Advisory Board

Creative Medical Technology Holdings Inc. Files Investigational New Drug Application with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Patent Filing Based on Preclinical Data in Model of Heart Attack Using ImmCelz Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke

Creative Medical Technology Holdings Files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘